Intrinsic value of CRISPR Therapeutics - CRSP

Previous Close

$36.39

  Intrinsic Value

$0.99

stock screener

  Rating & Target

str. sell

-97%

Previous close

$36.39

 
Intrinsic value

$0.99

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of CRSP stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  42
  43
  44
  45
  46
  48
  50
  51
  53
  55
  58
  60
  62
  65
  68
  71
  74
  77
  81
  84
  88
  92
  97
  101
  106
  111
  117
  122
  128
  134
Variable operating expenses, $m
  118
  121
  124
  128
  131
  136
  140
  145
  151
  157
  163
  169
  176
  184
  192
  200
  209
  218
  228
  239
  250
  262
  274
  287
  301
  315
  330
  346
  363
  380
Fixed operating expenses, $m
  60
  62
  63
  64
  66
  67
  69
  70
  72
  73
  75
  77
  78
  80
  82
  84
  85
  87
  89
  91
  93
  95
  97
  99
  102
  104
  106
  109
  111
  113
Total operating expenses, $m
  178
  183
  187
  192
  197
  203
  209
  215
  223
  230
  238
  246
  254
  264
  274
  284
  294
  305
  317
  330
  343
  357
  371
  386
  403
  419
  436
  455
  474
  493
Operating income, $m
  -137
  -140
  -143
  -147
  -151
  -155
  -159
  -164
  -169
  -175
  -180
  -186
  -192
  -199
  -206
  -213
  -221
  -228
  -237
  -246
  -255
  -264
  -274
  -285
  -296
  -307
  -320
  -332
  -345
  -359
EBITDA, $m
  -134
  -137
  -140
  -144
  -147
  -151
  -156
  -160
  -165
  -170
  -176
  -182
  -188
  -194
  -201
  -208
  -215
  -223
  -231
  -239
  -248
  -258
  -267
  -277
  -288
  -299
  -311
  -323
  -336
  -349
Interest expense (income), $m
  0
  0
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  0
  0
  0
  0
  0
  1
  1
  1
  1
  2
  2
Earnings before tax, $m
  -137
  -137
  -141
  -145
  -149
  -153
  -157
  -162
  -167
  -173
  -178
  -184
  -191
  -197
  -204
  -212
  -220
  -228
  -236
  -245
  -255
  -264
  -275
  -285
  -297
  -308
  -321
  -334
  -347
  -361
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -137
  -137
  -141
  -145
  -149
  -153
  -157
  -162
  -167
  -173
  -178
  -184
  -191
  -197
  -204
  -212
  -220
  -228
  -236
  -245
  -255
  -264
  -275
  -285
  -297
  -308
  -321
  -334
  -347
  -361

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  44
  45
  46
  47
  49
  50
  52
  54
  56
  58
  60
  63
  65
  68
  71
  74
  77
  81
  85
  88
  93
  97
  101
  106
  111
  117
  122
  128
  134
  141
Adjusted assets (=assets-cash), $m
  44
  45
  46
  47
  49
  50
  52
  54
  56
  58
  60
  63
  65
  68
  71
  74
  77
  81
  85
  88
  93
  97
  101
  106
  111
  117
  122
  128
  134
  141
Revenue / Adjusted assets
  0.955
  0.956
  0.957
  0.957
  0.939
  0.960
  0.962
  0.944
  0.946
  0.948
  0.967
  0.952
  0.954
  0.956
  0.958
  0.959
  0.961
  0.951
  0.953
  0.955
  0.946
  0.948
  0.960
  0.953
  0.955
  0.949
  0.959
  0.953
  0.955
  0.950
Average production assets, $m
  21
  21
  22
  22
  23
  24
  24
  25
  26
  27
  28
  29
  31
  32
  33
  35
  36
  38
  40
  41
  43
  45
  48
  50
  52
  55
  57
  60
  63
  66
Working capital, $m
  -9
  -9
  -10
  -10
  -10
  -11
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -26
  -27
  -28
  -30
Total debt, $m
  -44
  -43
  -42
  -41
  -40
  -38
  -37
  -35
  -33
  -31
  -29
  -27
  -25
  -22
  -20
  -17
  -14
  -11
  -7
  -4
  0
  4
  8
  12
  17
  21
  26
  32
  37
  43
Total liabilities, $m
  39
  40
  41
  43
  44
  45
  47
  48
  50
  52
  54
  56
  59
  61
  64
  67
  70
  73
  76
  80
  83
  87
  91
  96
  100
  105
  110
  115
  121
  127
Total equity, $m
  4
  4
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
Total liabilities and equity, $m
  43
  44
  46
  48
  49
  50
  52
  53
  56
  58
  60
  62
  66
  68
  71
  74
  78
  81
  84
  89
  92
  97
  101
  107
  111
  117
  122
  128
  134
  141
Debt-to-equity ratio
  -10.070
  -9.640
  -9.180
  -8.680
  -8.160
  -7.620
  -7.080
  -6.520
  -5.970
  -5.410
  -4.870
  -4.320
  -3.790
  -3.270
  -2.770
  -2.270
  -1.790
  -1.330
  -0.880
  -0.440
  -0.030
  0.380
  0.760
  1.140
  1.490
  1.840
  2.170
  2.480
  2.780
  3.070
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -137
  -137
  -141
  -145
  -149
  -153
  -157
  -162
  -167
  -173
  -178
  -184
  -191
  -197
  -204
  -212
  -220
  -228
  -236
  -245
  -255
  -264
  -275
  -285
  -297
  -308
  -321
  -334
  -347
  -361
Depreciation, amort., depletion, $m
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  9
  9
  9
  10
Funds from operations, $m
  -134
  -134
  -138
  -141
  -145
  -149
  -154
  -158
  -163
  -169
  -174
  -180
  -186
  -193
  -200
  -207
  -214
  -222
  -230
  -239
  -248
  -258
  -267
  -278
  -289
  -300
  -312
  -325
  -338
  -351
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -134
  -134
  -137
  -141
  -145
  -149
  -153
  -158
  -163
  -168
  -174
  -180
  -186
  -192
  -199
  -206
  -214
  -221
  -230
  -238
  -247
  -257
  -267
  -277
  -288
  -299
  -311
  -323
  -336
  -350
Maintenance CAPEX, $m
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -9
  -9
  -9
New CAPEX, $m
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
Cash from investing activities, $m
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -8
  -8
  -9
  -9
  -9
  -10
  -11
  -12
  -12
  -12
Free cash flow, $m
  -137
  -138
  -141
  -145
  -149
  -153
  -158
  -163
  -168
  -173
  -179
  -185
  -191
  -198
  -205
  -212
  -220
  -228
  -237
  -246
  -255
  -265
  -275
  -286
  -298
  -309
  -322
  -335
  -348
  -362
Issuance/(repayment) of debt, $m
  -44
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
Issuance/(repurchase) of shares, $m
  182
  138
  141
  145
  149
  153
  158
  162
  168
  173
  179
  185
  191
  198
  205
  212
  220
  228
  237
  246
  255
  265
  275
  286
  297
  309
  321
  334
  348
  362
Cash from financing (excl. dividends), $m  
  138
  139
  142
  146
  150
  154
  160
  164
  170
  175
  181
  187
  193
  200
  208
  215
  223
  231
  240
  249
  259
  269
  279
  290
  302
  314
  326
  339
  354
  368
Total cash flow (excl. dividends), $m
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
Retained Cash Flow (-), $m
  -182
  -138
  -141
  -145
  -149
  -153
  -158
  -162
  -168
  -173
  -179
  -185
  -191
  -198
  -205
  -212
  -220
  -228
  -237
  -246
  -255
  -265
  -275
  -286
  -297
  -309
  -321
  -334
  -348
  -362
Prev. year cash balance distribution, $m
  228
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  47
  -137
  -140
  -144
  -148
  -152
  -156
  -161
  -166
  -171
  -177
  -183
  -189
  -196
  -202
  -210
  -217
  -225
  -234
  -242
  -252
  -261
  -271
  -282
  -293
  -305
  -317
  -329
  -343
  -357
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  45
  -125
  -122
  -118
  -114
  -110
  -105
  -101
  -95
  -90
  -84
  -78
  -72
  -66
  -59
  -53
  -47
  -41
  -36
  -31
  -26
  -22
  -18
  -14
  -11
  -9
  -7
  -5
  -4
  -3
Current shareholders' claim on cash, %
  50.0
  11.3
  2.5
  0.6
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

FINANCIAL RATIOS  of  CRISPR Therapeutics (CRSP)

Valuation Ratios
P/E Ratio -62.8
Price to Sales 289.1
Price to Book 6.2
Price to Tangible Book
Price to Cash Flow -26.3
Price to Free Cash Flow -24.9
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -9.1%
Ret/ On Assets - 3 Yr. Avg. -213.8%
Return On Total Capital -15%
Ret/ On T. Cap. - 3 Yr. Avg. 370.9%
Return On Equity -17.2%
Return On Equity - 3 Yr. Avg. 343.3%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -440%
EBITDA Margin - 3 Yr. Avg. -146.7%
Operating Margin -1140%
Oper. Margin - 3 Yr. Avg. -380%
Pre-Tax Margin -460%
Pre-Tax Margin - 3 Yr. Avg. -153.3%
Net Profit Margin -460%
Net Profit Margin - 3 Yr. Avg. -153.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CRSP stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CRSP stock intrinsic value calculation we used $40.997 million for the last fiscal year's total revenue generated by CRISPR Therapeutics. The default revenue input number comes from 0001 income statement of CRISPR Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CRSP stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CRSP is calculated based on our internal credit rating of CRISPR Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CRISPR Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CRSP stock the variable cost ratio is equal to 282.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $59 million in the base year in the intrinsic value calculation for CRSP stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for CRISPR Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for CRISPR Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CRSP stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CRSP are equal to 49.1%.

Life of production assets of 6.7 years is the average useful life of capital assets used in CRISPR Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CRSP is equal to -22%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $187.832 million for CRISPR Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 47.187 million for CRISPR Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CRISPR Therapeutics at the current share price and the inputted number of shares is $1.7 billion.

RELATED COMPANIES Price Int.Val. Rating
CRSP CRISPR Therape 36.39 0.99  str.sell
SGMO Sangamo Therap 10.36 3.03  str.sell
EDIT Editas Medicin 28.08 1.10  str.sell
ONCE Spark Therapeu 39.00 3.43  str.sell
VRTX Vertex Pharmac 166.67 92.21  sell
BLUE bluebird bio 122.78 7.95  str.sell
CLLS Cellectis ADR 22.51 2.72  str.sell

COMPANY NEWS

▶ 3 DNA Stocks That Are on the Uptrend   [11:51AM  InvestorPlace]
▶ Cambridge's Editas asks FDA to start gene editing trial   [Nov-07-18 07:46PM  American City Business Journals]
▶ 3 Stocks to Buy and Hold for the Next 50 Years   [Oct-26-18 03:41PM  Motley Fool]
▶ 3 High-Reward Stocks From 3 Emerging Trends   [Oct-12-18 02:23PM  InvestorPlace]
▶ FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial   [12:48PM  American City Business Journals]
▶ Company News For Oct 12, 2018   [09:35AM  Zacks]
▶ After-hours buzz: SQ, FLR & more   [Oct-10-18 05:11PM  CNBC]
▶ FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial   [05:03PM  American City Business Journals]
▶ Better Buy: Crispr Therapeutics AG vs. Editas   [Oct-09-18 04:35PM  Motley Fool]
▶ After-hours buzz: TLRY, RHT & more   [Sep-19-18 05:03PM  CNBC]
▶ Stem Cell Deals Moving the Markets   [10:30AM  ACCESSWIRE]
▶ Is CRISPR Therapeutics AG a Buy?   [Sep-16-18 08:31AM  Motley Fool]
▶ Here's Why CRISPR Stocks Rose as Much as 18.7% in August   [Sep-04-18 11:29AM  Motley Fool]
▶ 3 Biotech Stocks That Could Soar Next Week   [Sep-02-18 09:10AM  Motley Fool]
▶ Gene Editing is a Major Technology to Watch   [Aug-27-18 01:12PM  InvestorPlace]
▶ 3 Relatively Safe Ways to Invest in Gene Editing   [Aug-24-18 08:16AM  Motley Fool]
▶ Is Crispr Therapeutics Stock Grossly Overvalued?   [Aug-09-18 10:00AM  Motley Fool]
▶ Here's Why CRISPR Therapeutics Lost 18.8% in July   [Aug-04-18 12:28PM  Motley Fool]
▶ [$$] CRISPR Technology Still Holds Big Promise   [Aug-03-18 01:38PM  Barrons.com]
▶ Here's Why CRISPR Stocks Are Down as Much as 11.4% Today   [Jul-24-18 04:06PM  Motley Fool]
▶ Yet Another CRISPR Worry: What Should Investors Do?   [Jul-17-18 03:01PM  Motley Fool]
▶ [$$] New Research Prompts Selloff in Companies Using Crispr Technology   [Jul-16-18 07:31PM  The Wall Street Journal]
▶ Here's Why CRISPR Therapeutics AG Fell 14.7% in June   [Jul-09-18 01:26PM  Motley Fool]
▶ The 2 Most Wildly Overvalued Biotech Stocks Right Now   [Jul-01-18 10:02AM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.